The p53 Tumor Suppressor Is Stabilized by Inhibitor of Growth 1 (ING1) by Blocking Polyubiquitination

• Subhash Thalappilly ,

  Contributed equally to this work with: Subhash Thalappilly, Xiaolan Feng

  Affiliation Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada

  ⨯
• Xiaolan Feng ,

  Contributed equally to this work with: Subhash Thalappilly, Xiaolan Feng

  Affiliation Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada

  ⨯
• Svitlana Pastyryeva,

  Affiliation Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada

  ⨯
• Keiko Suzuki,

  Affiliation Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada

  ⨯
• Daniel Muruve,

  Affiliation Department of Medicine, University of Calgary, Calgary, Alberta, Canada

  ⨯
• Daniel Larocque,

  Affiliation Preclinical Research Team on Neurodegenerative Diseases, Chronic Disorders DAP, GlaxoSmithKline Biologicals North America, Laval, Quebec, Canada

  ⨯
• Stephane Richard,

  Affiliation Department of Medicine and Oncology, Lady Davis Institute, McGill University, Montreal, Quebec, Canada

  ⨯
• Matthias Truss,

  Affiliation Laboratory for Molecular Biology, Department of Pediatrics, Charité - Universitätsmedizin Berlin, Berlin, Germany

  ⨯
• Andreas von Deimling,

  Affiliation Department of Neuropathology, Institute of Pathology, Ruprecht-Karls University Heidelberg and Clinical Cooperation Unit Neuropathology, Heidelberg, Germany

  ⨯
• Karl Riabowol,

  Affiliation Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada

  ⨯
• Gesche Tallen

  * E-mail: gesche.tallen@charite.de

  Affiliation Department of Pediatric Oncology/Haematology, Charité - Universitätsmedizin Berlin, Berlin, Germany

  ⨯